Before you begin using a medication, be sure to inform your doctor of any medical conditions or allergies you may have, any medications you are taking, whether you are pregnant or breast-feeding, and any other significant facts about your health. These factors may affect how you should use this medication.
Eye problems: Pegaptanib can cause eye problems after injections such as infection of the inside part of the eye; pain, redness, or inflammation; detachment or tear of the retina; or clouding of the lens. Contact your doctor immediately if you experience any of the following:
- blurred or reduced vision
- eye pain
- increased eye discomfort
- increased sensitivity of the eyes to light
- an increase in the number of small particles in your vision
- worsening eye redness
Increased eye pressure: Pegaptanib can increase the pressure in the eye for a short period of time after it is injected. Your doctor will do tests to make sure the pressure in your eye is not elevated persistently after treatment.
Kidney and liver problems: If you have decreased kidney or liver function, discuss with your doctor how this medication may affect your medical condition, how your medical condition may affect the dosing and effectiveness of this medication, and whether any special monitoring is needed.
Vision problems: Pegaptanib can cause temporary vision problems, which may affect the ability to drive or operate machines. If you experience vision problems, do not drive or operate machines until your vision returns to normal.
Pregnancy: The medication should not be used during pregnancy unless the benefits outweigh the risks. If you become pregnant while taking this medication, contact your doctor immediately.
Breast-feeding: It is not known if pegaptanib passes into breast milk. If you are a breast-feeding mother and are taking this medication, it may affect your baby. Talk to your doctor about whether you should continue breast-feeding.
Children: The safety and effectiveness of using this medication have not been established for children.